1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
InnSuites Hospitality Trust said NYSE American accepted its compliance plan and granted a plan period through December 24, 2027. The Trust is not currently in compliance with NYSE American continued listing standards, but its listing continues under the extension, and staff could start delisting proceedings if the Trust does not meet the standards or make progress under the plan.
NYSE American notice received September 10, 2026; plan period runs through December 24, 2027
Trust increased stockholders' equity by $3 million on August 19, 2026, as one step toward compliance
Consolidated net income for the Fiscal First Quarter was $74,702, up 48% from the prior year quarter
Filing states there is no assurance the Trust will regain compliance or complete any proposed transaction
FatPipe appointed Kanishka Ragula, age 25, as Chief Financial Officer and Principal Accounting Officer effective September 11, 2026, replacing Eric Sherb, who ceased serving in those roles on the same date. The filing says Sherb's departure was not the result of any disagreement with the company and that he will consult for FatPipe during the transition. Ragula's family relationship to the CEO and Chairman is disclosed, which shareholders may weigh when assessing the appointment.
Eric Sherb ceased serving as CFO and Principal Accounting Officer effective September 11, 2026, and will continue as a consultant.
Kanishka Ragula, age 25, was appointed CFO and Principal Accounting Officer effective September 11, 2026; he had been Director of Finance since September 2025.
Ragula will receive an annual base salary of $175,000 plus an equity grant to be approved by the board at the annual meeting.
Ragula is the son of CEO and Chairman Ragula Bhaskar, Ph.D., and of President, CTO and director Sanchaita Datta.
On September 14, 2026, Hyperliquid Strategies Inc and Chardan Capital Markets LLC signed Amendment No. 3 to their ChEF Purchase Agreement, replacing the definition of VWAP Purchase Price. After the first 160,000,000 shares are sold under the agreement, the company's VWAP-based and Intraday VWAP sales are priced at 98.5% of VWAP, and Off-Hour VWAP sales at 97.0% of VWAP. The filing does not state the number of shares expected to be sold, so its effect on existing shareholders cannot be measured from this document.
Amendment No. 3 dated September 14, 2026, amends the ChEF Purchase Agreement dated October 22, 2025, with Chardan Capital Markets LLC.
After the first 160,000,000 shares are sold, VWAP and Intraday VWAP purchases are priced at 98.5% of the VWAP over the applicable period.
Off-Hour VWAP purchases are priced at 97.0% of the VWAP; the amendment supersedes Amendment No. 2 dated September 14, 2026.
Impact Biomedical Inc. (NYSE American: IBO) said its 1-for-12.62 reverse stock split will take effect at 12:01 a.m. Eastern Time on September 23, 2026, reducing outstanding common shares from about 107.8 million to about 8.5 million. The company said the split is connected to its proposed merger with Zoar Limited and to regaining compliance with NYSE American listing requirements, but it gave no assurance that either goal will be met. The filing also corrects an earlier press release that misstated the merger exchange ratio.
Reverse split ratio of 1-for-12.62 takes effect 12:01 a.m. Eastern Time on September 23, 2026; ticker remains IBO under a new CUSIP.
Shares outstanding expected to fall from 107,821,231 to 8,543,679, subject to rounding; fractional shares are rounded up to the next whole share.
Merger terms: one Zoar Limited share for each Impact share held immediately before the merger, after giving effect to the split.
A corrected press release replaces the September 11, 2026 release, which incorrectly stated a one-for-four exchange ratio.
On September 14, 2026, Tyra Biosciences agreed to sell 9,079,000 shares of common stock and pre-funded warrants for 9,078,529 shares, with gross proceeds expected to be approximately $400.0 million before underwriting discounts and offering expenses. The offering is expected to close on September 15, 2026, and the company plans to use the net proceeds, together with existing cash, to advance its dabogratinib 3x3 development strategy, support preclinical and discovery programs, and fund working capital and general corporate purposes. Issuing these shares and warrants will dilute existing shareholders.
Offering of 9,079,000 common shares at $22.03 per share, plus pre-funded warrants for 9,078,529 shares at $22.029 per warrant
Underwriters agreed to buy the shares at $20.7082 per share; gross proceeds expected to be approximately $400.0 million
Closing expected September 15, 2026; proceeds targeted at dabogratinib 3x3 in LG-UTUC, IR NMIBC and achondroplasia
On September 14, 2026, The Trade Desk's board approved a performance-based stock option for CEO Jeff Green, who recused himself from the vote. The option allows him to buy up to 7,000,000 Class A shares at $14.97, the closing price on the grant date, but shares vest only if the stock reaches price targets from $18.00 to $105.00.
Up to 7,000,000 Class A shares under the option, with an exercise price of $14.97 per share
Seven vesting tranches with price targets from $18.00 to $105.00 per share, over a ten-year term
Vesting requires the average closing price to meet a target over any 20-consecutive-trading-day period, plus continued service
The award agreement will be filed with the Form 10-Q for the quarter ending September 30, 2026
BOXABL concluded the employment of CFO Martin Costas effective September 11, 2026, and appointed Larry King as CFO effective September 14, 2026. The company also said Heather Clayton will become Chief Accounting Officer beginning September 28, 2026. The filing says Costas's departure was not due to any disagreement with the company on operations, policies, or practices.
Martin Costas's employment as CFO concluded effective September 11, 2026; the filing states no disagreement with the company was the reason.
Larry King, 65, a Certified Public Accountant, was appointed CFO and principal financial and accounting officer effective September 14, 2026, with an annual salary of $300,000.
Heather Clayton will begin as Chief Accounting Officer on September 28, 2026, with an annual salary of $250,000.
Offer letters for King and Clayton are filed as Exhibits 10.1 and 10.2.
Calumet, Inc. entered into an amendment to its credit agreement on September 11, 2026, increasing lender commitments from $500.0 million to $600.0 million, subject to borrowing base limitations. A related amendment to its Monetization Master Agreement with J. Aron & Company LLC was made to permit the larger credit facility. The filing does not state the reasons for the change or any effect on earnings, and shareholders can expect more borrowing capacity under the facility.
Credit agreement commitments rise from $500.0 million to $600.0 million, subject to borrowing base limitations
Eleventh Amendment to the Third Amended and Restated Credit Agreement dated September 11, 2026, with Bank of America, N.A. as administrative agent
Fourth Amendment to the Monetization Master Agreement with J. Aron & Company LLC, dated September 11, 2026, permits the increase
Filed under Items 1.01, 2.03 and 9.01; signed by David Lunin, Executive Vice President and Chief Financial Officer, on September 14, 2026
Eagle Point Credit Company disclosed in an 8-K filed September 14, 2026, that management's unaudited estimate of its net asset value per common share as of August 31, 2026 was between $4.29 and $4.39. The filing gives only the range and no prior-period comparison, so it does not show whether NAV rose or fell from the prior month.
Unaudited estimated NAV per common share range: $4.29 to $4.39
Estimate is as of August 31, 2026
Filed under Item 8.01 (Other Events) on September 14, 2026; signed by CFO and COO Kenneth P. Onorio
Clean Energy Technologies received $150,000 in net funding from Walnut Capital through a convertible promissory note with a $166,500 principal amount, closed September 9, 2026. The note matures September 8, 2027, carries a one-time 12% interest charge, and can convert into common stock after default at 85% of the lowest closing bid price over the prior ten trading days, which could add dilution for shareholders.
Principal amount of $166,500 for a purchase price of $150,000, closed September 9, 2026
Note matures September 8, 2027, with a one-time 12% interest charge and 10 monthly payments of $18,648 starting December 8, 2026
Conversion after default at 85% of the lowest closing bid price in the prior ten trading days; holder fees of $1,500 deducted per conversion
Proceeds required to be used for general working capital; note sold without registration under Section 4(a)(2)
Radiant Logistics reported fourth-quarter results for the three months ended June 30, 2026, with revenue of $261.4 million, up 18.5%, and GAAP net income attributable to the company of $7.5 million, up 53.1%. For the full fiscal year, GAAP net income rose to $18.8 million, but adjusted EBITDA fell to $36.7 million from $38.8 million and adjusted net income fell to $25.3 million from $30.9 million, so shareholders see stronger quarterly growth alongside lower full-year adjusted profit.
Q4 revenue $261.4 million, up $40.8 million or 18.5%; Q4 diluted EPS $0.15 versus $0.10 a year earlier
Q4 adjusted EBITDA $10.4 million, up 31.6%; adjusted EBITDA margin 15.5%, up 240 basis points
Full-year revenue $934.4 million versus $902.7 million; full-year adjusted EBITDA $36.7 million versus $38.8 million
On August 7, 2026, the $200 million revolving credit facility was extended to August 7, 2031; the company reported no net debt as of June 30, 2026
On September 14, 2026, Plains All American Pipeline, L.P. (PAA), a wholly owned subsidiary of PAGP, completed a public offering of $700 million of 6.750% Series A notes and $800 million of 7.000% Series B notes, both due December 15, 2056. The notes are unsecured, rank junior to PAA's existing and future senior debt, and are not guaranteed by PAA's subsidiaries. The filing also provides unaudited pro forma 2025 results that show revenue slightly higher but per-share net income from continuing operations lower than reported, reflecting the EPIC Crude Holdings acquisitions.
Series A: $700 million, 6.750% junior subordinated notes due December 15, 2056; interest first payable June 15, 2027.
Series B: $800 million, 7.000% junior subordinated notes due December 15, 2056; rates may reset on December 15, 2036 and every five years after.
Pro forma 2025 revenue of $44,464 million versus $44,262 million historical; net income per Class A share of $0.68 versus $0.77 historical.
Underwriters were J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Mizuho Securities USA LLC, MUFG Securities Americas Inc. and Truist Securities, Inc.
Addus HomeCare's subsidiary agreed on September 12, 2026 to acquire the personal care business of AccentCare outside New York for $275 million in cash, subject to adjustments. The company expects the deal to add about $280 million in annualized revenue, which it says would be roughly a 19% increase to its revenue base, and plans to fund it through its revolver and cash on hand. Closing depends on regulatory approvals and the Hart-Scott-Rodino waiting period, so shareholders will not see the deal's effect until it closes.
Purchase price is $275 million in cash, subject to working capital and other customary adjustments.
Company expects about $280 million in annualized personal care revenue, which its CEO describes as roughly a 19% increase to revenue.
Acquired operations serve an average daily census of about 13,700 customers across a 10-state footprint.
Closing requires regulatory approvals and the expiration of the HSR waiting period; the deal has no financing condition and no termination or reverse termination fee.
NextEra Energy and Dominion Energy issued a joint press release on September 14, 2026, announcing an enhanced Virginia benefits package under their pending Merger Agreement. The package proposes doubling $10 per month residential bill credits from two years to four years, a $100 million increase to the EnergyShare low-income assistance program, and new jobs and a Richmond office tower. The companies say these commitments depend on approval and closing of the combination, which they expect in the second half of 2027, so the filing does not change the financial results of either company.
Residential bill credits of $10 per month would run four years instead of two.
EnergyShare low-income assistance would increase by $100 million through 2038.
NextEra plans 600 new jobs in Virginia and a $100 million workforce development fund; the companies expect the transaction to close in the second half of 2027.
Z Squared completed its acquisition of Paradox Data, LLC on September 8, 2026, which holds the Union County Campus in El Dorado, Arkansas, with about 8.0 MW of existing interruptible grid power. The company paid with 5,000 shares of newly designated Series A Convertible Preferred Stock, with a stated value of $5,000,000, and issued no cash or debt for the closing. Shareholders should note the preferred stock's potential dilution, a related person transaction involving the Chief Technology Officer, and that Entergy's consent to transfer the power agreement has not been obtained.
Closing date September 8, 2026; consideration was 5,000 Series A Preferred shares with a $5,000,000 stated value, convertible at $7.45 per common share
Up to $20,000,000 more in preferred stock is payable on development milestones, none achieved; total potential consideration up to $25,000,000
Chief Technology Officer Jeffery Harris holds an indirect minority interest in the seller and in Paradox Energy LLC; the Audit Committee and Board approved the deal
Entergy Arkansas consent to assign the electric service agreement has not been obtained; the 150 MW target is not contracted or energized
Boxlight received a Nasdaq Hearings Panel decision on September 2, 2026 that it has regained compliance with the $2.5 million stockholders' equity requirement and may continue listing on Nasdaq. The Panel also imposed a one-year monitoring period, so any future Nasdaq rule noncompliance could lead directly to a delisting determination without a cure period.
Panel decision dated September 2, 2026 found compliance with the $2,500,000 stockholders' equity rule (Rule 5550(b)(1)).
Compliance plan relied on a Series D preferred financing: $4.8 million raised in Tranche One on August 5, 2026, with about $6.6 million in net proceeds for the full PIPE transaction.
One-year Discretionary Panel Monitor effective August 17, 2026; any new noncompliance may lead to a Delist Determination Letter.
Review of the decision may be requested within 15 calendar days, subject to a $15,000 fee.
On September 8, 2026, Odyssey and American Ocean Minerals (AOM) amended their note purchase agreement, including a $500,000 initial note that AOM will buy on September 9, 2026. The amendment allows further advances beyond the previously stated maximums, caps each note category at $5.0 million unless AOM agrees otherwise, and expands permitted use of proceeds to expenses incurred through the merger. The notes are secured by substantially all of Odyssey's assets, so the added financing increases the claims ranked ahead of shareholders.
Amendment dated September 8, 2026 provides for an additional $500,000 Initial Note purchased by AOM on September 9, 2026.
Notes bear 8.0% annual interest, rising to 11.0% after an interest payment default, and are secured by substantially all of Odyssey's assets.
Principal and accrued interest are due on the earlier of April 8, 2027, or the closing of the merger under the agreement dated April 8, 2026.
AOM bought a $700,000 Pre-Closing Note on May 28, 2026; each note category is capped at $5.0 million unless AOM agrees in writing.
On September 14, 2026, Amazon closed the sale of four series of notes with a total public offering price of £4.242 billion and estimated net proceeds of about £4.235 billion before offering expenses. The notes carry coupons from 5.200% to 6.650% and mature between 2029 and 2045, so the filing shows new long-term debt that Amazon will need to repay and service.
Four series: 5.200% notes due 2029 (£1.25 billion), 5.550% due 2032 (£1 billion), 6.250% due 2038 (£1 billion), 6.650% due 2045 (£1 billion)
Aggregate public offering price of £4.242 billion; estimated net proceeds of about £4.235 billion before offering expenses
Sold under an Underwriting Agreement dated September 9, 2026, and registered on a Form S-3 filed February 6, 2026
VolitionRX prepaid in cash the outstanding principal of its $7.5 million senior secured convertible note issued to Lind Global Asset Management XII LLC, with the prepayment made on September 11, 2026, and the company says no further amounts remain outstanding under that note. The company says the prepayment prevents further potential dilution to stockholders from the note, and the separate $2.4 million 2026 Note remains in effect.
Prepayment of approximately $422,000 made September 11, 2026 under Section 1.4.1 of the 2025 Note
The $7.5 million 2025 Note, dated May 20, 2025, is fully satisfied; the 2026 Note remains outstanding at $2,041,667 per the press release
CEO Cameron Reynolds said the note was retired more than eight months ahead of its originally scheduled maturity
CitroTech amended its stockholder agreements with BoltRock Holdings, LLC and TC Special Investments LLC, replacing their board appointment rights with nomination rights that depend on continued ownership. The same day, the company made an investor presentation available that repeats management's going concern conclusion from its August 2026 quarterly report and shows Q2 2026 revenue below the prior-year quarter.
Amendments dated September 14, 2026 replace board appointment rights with rights to designate one nominee, for as long as each holder keeps at least one divided by the total number of board seats in voting power
Rights end permanently if the ownership threshold is no longer met; a non-voting board observer right applies when no designated nominee is serving
Investor presentation says management concluded there is substantial doubt about the company's ability to continue as a going concern, as disclosed in the Form 10-Q filed August 10, 2026
Presentation shows Q2 2026 revenue of $281,000 versus $688,000 in Q2 2025
DexCom named Jereme Sylvain, its executive vice president and chief financial officer, to also serve as chief operating officer, effective September 14, 2026, with oversight of global operations and quality teams. His new offer letter sets a base salary of $767,000 and a target bonus of 75% of base salary.
Sylvain keeps his CFO role and adds the COO title, effective September 14, 2026
Base salary of $767,000; annual target bonus equal to 75% of base salary
Offer letter dated September 11, 2026; a copy will be filed with the 10-Q for the quarter ended September 30, 2026
CEO Jake Leach said Sylvain will help the company scale more effectively
On September 8, 2026, Drugs Made In America Acquisition Corp. and Power Analytics Global Corp entered an Amended and Restated Definitive Merger Agreement that replaces the existing agreement in its entirety. The parties set a fixed closing valuation of $2.85 billion for Power Analytics, replacing the prior $1.0 billion target and $300 million floor. Completion depends on conditions including shareholder approval, an acquisition of APQC Inc, and a minimum cash condition, so the deal has not closed.
Amended and Restated Definitive Merger Agreement dated September 8, 2026, replacing the Existing Agreement from April 29, 2026.
Closing valuation of $2.85 billion, replacing the $1.0 billion target valuation and $300 million floor valuation.
Merger Consideration capped at 265,116,279 Domesticated DMAA Common Shares, based on a Reference Price of at least $10.75.
Closing requires shareholder approval, completion of the APQC Acquisition and Available Closing Cash of at least $15 million.
Firefly Neuroscience's board terminated Chief Financial Officer Paul Krzywicki on September 8, 2026, effective September 24, 2026, and stated the decision was not the result of any disagreement over the company's operations, policies or practices. The company also appointed Jessica Paz as Chief Accounting Officer, with an annual base salary of $215,000 and a stock option for 50,000 shares. The filing does not name a successor CFO.
Board terminated CFO Paul Krzywicki on September 8, 2026, effective September 24, 2026
Termination was stated to be unrelated to any disagreement on operations, policies or practices
Jessica Paz employed as Chief Accounting Officer effective September 8, 2026, at $215,000 annual base salary
Paz received a stock option for 50,000 shares, vesting over four years with 25% after the first anniversary
Plains All American Pipeline completed a public offering of $700 million of 6.750% Series A notes and $800 million of 7.000% Series B notes, both due December 15, 2056. The notes are unsecured and rank junior to PAA's existing and future senior debt, so holders would be paid after senior creditors, and no subsidiaries guarantee them. The filing shows the company is adding $1.5 billion in debt-like obligations, with interest rates that can reset in 2031 and 2036, subject to a floor at the initial rate.
Series A: $700 million, 6.750% coupon, due December 15, 2056; rate can adjust December 15, 2031 and every five years after.
Series B: $800 million, 7.000% coupon, due December 15, 2056; rate can adjust December 15, 2036 and every five years after.
Interest is payable June 15 and December 15, starting June 15, 2027; rates cannot reset below the initial rate.
Underwriting agreement dated September 9, 2026 with J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and others; notes sold under a Form S-3 shelf filed September 6, 2024.
Genasys Inc. entered into a First Amendment to its loan agreement with Maran Partners Fund, LP, dated September 14, 2026, and reported it under Item 2.03 as a direct financial obligation. The filing does not state the amendment's amount, interest rate, maturity or changed terms in the text provided, so shareholders cannot yet judge its size or cost from this document.
Amendment is dated September 14, 2026, between Genasys Inc. and Maran Partners Fund, LP (Exhibit 10.1).
The filing is made under Items 1.01, 2.03 and 9.01; the Item 1.01 disclosure it incorporates is not included in the text provided.
No loan amount, interest rate or revised repayment terms are stated in the text provided.
Filing was signed by Chief Financial Officer Cassandra L. Hernandez-Monteon.
Crown Castle said CFO Sunit Patel will retire effective March 31, 2027, and that its board intends to appoint EVP and Chief Commercial Officer Kristoffer Hinson as CFO effective April 1, 2027. COO Cathy Piche will step down from her COO role on September 23, 2026, serve as a special advisor, and leave the company on February 22, 2027, with a search for her successor underway. The changes affect two senior executive roles, and no compensation terms for Hinson have been set yet.
Sunit Patel retires as EVP and CFO effective March 31, 2027, after the 2026 Form 10-K is filed.
Kristoffer Hinson, currently EVP and Chief Commercial Officer, is intended to become EVP and CFO effective April 1, 2027.
Cathy Piche leaves the COO role September 23, 2026, serves as special advisor, and departs February 22, 2027.
Hinson's compensation arrangements have not been determined; any required changes will be disclosed by amendment to this 8-K.
Health Catalyst appointed Tami Reller as a Class III director, effective October 1, 2026, expanding the board from six to seven members. She will also chair the Audit Committee and join the Compensation Committee. The company's press release also states that Simeon Kohl was named Chief Executive Officer and President, effective September 14, 2026.
Tami Reller appointed to the board effective October 1, 2026, filling a newly created seat
Board expands from six to seven directors, effective October 1, 2026
Reller replaces Justin Spencer as Audit Committee chair; Spencer remains on the committee
Press release states Simeon Kohl was named CEO and President effective September 14, 2026
American Tower completed a registered offering of $1.6 billion in senior unsecured notes across three maturities, with net proceeds of about $1,579.9 million. The company plans to use the proceeds to repay $600.0 million of 1.450% notes due 2026, repay borrowings under its $6.0 billion revolving credit facility, and for general corporate purposes. The new debt adds to the company's obligations, with interest rates from 5.300% to 5.750%.
Three tranches: $500.0 million 5.300% notes due September 15, 2031; $500.0 million 5.560% notes due September 15, 2033; $600.0 million 5.750% notes due September 15, 2036
Net proceeds of approximately $1,579.9 million after commissions and estimated expenses
Proceeds earmarked to repay $600.0 million of 1.450% notes due 2026 and revolver borrowings under the $6.0 billion facility
Interest is payable semi-annually beginning March 15, 2027; the notes are issued under a trustee, U.S. Bank Trust Company, National Association
Lululemon appointed Heidi O'Neill as chief executive officer and as a member of its board on September 8, 2026, ending the interim co-CEO roles of Meghan Frank and Andre Maestrini. The same day, the board adopted bylaw amendments covering stockholder nominations, meeting procedures and emergency operations, which shareholders may wish to review in the filed bylaws.
Heidi O'Neill began service as CEO and joined the board on September 8, 2026; the board increased from 11 to 12 members
Meghan Frank and Andre Maestrini ceased serving as interim co-CEOs as of September 8, 2026
Bylaws amended September 8, 2026, effective immediately, to update stockholder nomination and proposal procedures for universal proxy cards
A new Article XIII adds emergency bylaws for emergencies or disasters; full text filed as Exhibit 3.1
Dave & Buster's reported second quarter 2026 results for the period ended August 4, 2026, in a press release furnished as Exhibit 99.1. Revenue fell 2.4% to $544.1 million, the company swung to a net loss of $12.5 million, and Adjusted EBITDA dropped to $98.9 million from $129.8 million a year earlier, which weighs on shareholders.
Total revenue of $544.1 million, down 2.4% from $557.4 million in the second quarter of fiscal 2025; comparable store sales fell 2.9%.
Net loss of $12.5 million, or $0.36 per diluted share, versus net income of $11.4 million, or $0.32 per diluted share, a year earlier.
Adjusted EBITDA of $98.9 million versus $129.8 million; adjusted free cash flow was positive $19.5 million for the six months ended August 4, 2026, compared with negative $36.5 million a year earlier.
Available liquidity of $492.1 million at quarter end; the company opened six new domestic stores in the quarter.
Magnolia Oil & Gas completed its acquisition of WildFire Energy I LLC on September 10, 2026. The purchase price combined $2,570 million in cash, subject to final customary adjustments, 32,203,000 shares of Magnolia common stock, and the assumption of WildFire's $600.0 million 7.500% Senior Notes due 2029. The filing states that the share issuance was made under a Securities Act exemption and that resale registration rights were granted to the seller.
Acquisition completed September 10, 2026, with cash consideration of $2,570 million subject to final customary adjustments.
Equity consideration of 32,203,000 shares of common stock issued to seller WildFire Energy I LLC, with a 30-day lock-up on those shares.
Magnolia assumed the $600.0 million 7.500% Senior Notes due 2029, which mature October 15, 2029.
Magnolia Midstream LLC became a guarantor of Magnolia's 6.875% Senior Notes due 2032 and 6.625% Senior Notes due 2034.
First Citizens BancShares closed a public offering of 300,000 depositary shares, each a 1/100th interest in its new 7.500% Non-Cumulative Perpetual Preferred Stock, Series F, following a September 9, 2026 underwriting agreement. The new preferred ranks ahead of common stock and junior securities on dividends and liquidation, and carries no maturity date. Dividends are non-cumulative and payable only when declared by the board, so holders of common stock are not directly affected by the offering itself.
Offering of 300,000 depositary shares, each representing 1/100th of a $100,000 Series F preferred share, or $1,000 per depositary share; offering closed September 14, 2026
Dividend rate of 7.500% per annum until September 15, 2031, then resets to the five-year treasury rate plus 2.894%
Company may redeem on or after September 15, 2031, or within 90 days after a Regulatory Capital Treatment Event, subject to Federal Reserve approval
Holders elect two directors only if dividends are unpaid for periods totaling 18 months
Sionna Therapeutics said its Board approved a restructuring on September 9, 2026, that cuts about 46% of its workforce and winds down the SION-719 add-on program, with aggregate charges currently estimated at about $6.4 million. The company said the changes are meant to focus resources on the SION-451 and SION-2222 dual combination and extend its cash runway into the second half of 2029. Its Chief Business Officer's employment is ending, and the company is repricing employee stock options.
Restructuring charges are estimated at about $6.4 million, including $5.3 million in employee severance and other post-employment benefits, $0.7 million in SION-719 contract close-out costs and $0.4 million in stock-based compensation.
Workforce reduction and vendor wind-down are expected to be substantially complete by the end of the third quarter of 2026.
The company had about $268.3 million in cash, cash equivalents and marketable securities at the end of Q2 2026, and expects its runway to extend into the second half of 2029.
Chief Business Officer Caroline Stark Beer's employment ends September 15, 2026; option repricing takes effect September 17, 2026.
Veracyte, Inc. completed its acquisition of Convergent Genomics on September 14, 2026, through a merger under an agreement signed September 10, 2026, adding the UroAmp urine tumor DNA platform for bladder cancer. The filing states the company did not update its previously provided 2026 adjusted EBITDA guidance, which already contemplated Convergent's operating expenses, and no financial results for Convergent were disclosed.
Upfront cash consideration of $150 million, subject to customary purchase price adjustments
Up to $30 million in additional cash tied to UroAmp publication and reimbursement milestones
Merger agreement dated September 10, 2026; closing completed September 14, 2026
Veracyte expects to commercialize its first UroAmp-based test in late 2028, subject to reimbursement timelines
Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder did not achieve its primary efficacy endpoint. Johnson & Johnson, which develops the drug under a global license and development agreement, is still evaluating the data, including prespecified exploratory endpoints, to decide next steps.
Trial did not meet its primary efficacy endpoint, measured as change from baseline in MADRS total score at Day 5 versus placebo.
JNJ-5120/PIPE-307 was well-tolerated with no new safety signals.
Johnson & Johnson continues to assess the totality and clinical relevance of the findings to inform next steps for the drug.
Analyses of the data, including prespecified exploratory endpoints, are ongoing.
INmune Bio's board increased its size to seven directors and appointed R. Duane Clark II and James Sapirstein as independent directors on September 8, 2026, with both also joining the Nominating and Corporate Governance Committee. The company says the appointments add rare-disease commercialization and business-development experience as it prepares its Ebstrocel candidate for potential commercialization.
Board set at seven directors; Clark and Sapirstein appointed on September 8, 2026, serving until the next annual election
Each director to receive an option to purchase 100,000 shares of common stock, vesting in 36 equal monthly installments
Each director to receive an annual cash retainer of $50,000, paid quarterly in arrears
Clark is General Manager, U.S. Rare Diseases at Sanofi; Sapirstein is CEO of Cocrystal Pharma, Inc. (Nasdaq: COCP)
Kestra Medical Technologies reported first quarter fiscal 2027 revenue of $31.0 million, up 60% from the prior year period, and raised its FY27 revenue guidance to $141 million from $137 million. The GAAP net loss widened to $44.1 million from $25.8 million, so revenue growth came with larger losses for shareholders.
Revenue was $31.0 million for the quarter ended July 31, 2026, up 60% from the prior year period; gross margin was 56.5% versus 45.7%.
GAAP net loss was $44.1 million, or $0.75 per share, compared with $25.8 million, or $0.50 per share, a year earlier.
FY27 revenue guidance was increased to $141 million, growth of 48% over FY26, from prior guidance of $137 million.
Cash, cash equivalents and investments totaled $244.7 million as of July 31, 2026; total liquidity was about $320 million including committed unused term loan availability.
Yarrow Bioscience entered an underwriting agreement on September 10, 2026, to sell 5,769,231 common shares at $26.00 per share, and the underwriters exercised in full their option to buy 865,384 more shares on September 11, 2026. The company expects net proceeds of about $161.8 million, with closing expected on September 14, 2026. The sale adds new shares outstanding, which dilutes existing shareholders, and directors and executive officers agreed to a 60-day lock-up on selling their shares.
Base offering of 5,769,231 shares at $26.00 per share, underwritten by Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC
Underwriters exercised in full their 30-day option on September 11, 2026, for up to 865,384 additional shares
Expected net proceeds of about $161.8 million after underwriting discounts and estimated offering expenses
Offering made under a Form S-3 shelf registration effective August 19, 2026; closing expected September 14, 2026; directors and executive officers subject to a 60-day lock-up
QVC Group filed its Monthly Operating Report for July 2026 with the U.S. Bankruptcy Court for the Southern District of Texas, as required during its Chapter 11 case. The report shows a July net loss of $42.3 million on $295.8 million of gross sales, and a net deficit of $5.8 billion. The company says the figures are unaudited, preliminary, and not meant for investment decisions, so they may change materially.
July 2026 gross income (sales, net of returns and allowances): $295.8 million
July 2026 profit (loss): $42.3 million loss; cumulative column shows a $104.0 million loss
Cash balance at end of July 2026: $200.6 million; total liabilities: $7.9 billion
Report filed September 11, 2026; Plan became effective August 6, 2026 after July 20 court confirmation
Chatham Lodging Trust appointed William P. (Liam) Brown to its Board of Trustees effective immediately, following a board recommendation on September 10, 2026. Brown retired in June 2026 as Marriott's Group President for the United States and Canada, a role covering more than 6,000 hotels, and he will serve as an independent director until the 2027 annual meeting.
Appointment made September 10, 2026, effective immediately; Brown serves until the 2027 annual meeting of shareholders
Brown was Group President, United States and Canada of Marriott from January 2021 until his retirement in June 2026
Brown receives a one-time initial grant of 5,000 restricted common shares plus standard board compensation
Brown also sits on the board of EPR Properties (NYSE: EPR) since September 6, 2024
On September 14, 2026, Ondas Inc. completed its acquisition of Gate Technologies Ltd., an Israeli maker of electronic safe-and-arm devices, and Bron Technologies sp. z.o.o., a Polish manufacturer. The 8-K lists $105.0 million in cash and 10,689,655 shares of common stock at closing, plus a $25 million working capital adjustment, with up to $185 million in earn-out payments over two years. Ondas expects the acquired business to contribute more than $130 million of Adjusted EBITDA through 2028, and the new shares can be resold only within volume limits set by a registration rights agreement.
Closing payment of $105.0 million in cash and 10,689,655 shares of common stock, plus a $25 million working capital adjustment
About $22.5 million more to be issued within nine months of the Closing Date, subject to post-closing obligations of the Indemnifying Parties
Up to $185 million in contingent earn-out payments over two years after closing, payable in common stock per the 8-K
Shareholders may sell no more than 15% of average daily trading volume in any single trading day under the registration rights agreement
Onconetix agreed on September 11, 2026 to lend up to $5.0 million to Realbotix, LLC, the target of its pending all-stock acquisition, with $2.5 million advanced at signing. The loan is non-interest bearing until the acquisition closes or is terminated, and the balance is cancelled at closing, which reduces the cash Onconetix must hold at closing. For shareholders, the filing shows the financing terms but no change to the acquisition's status, which still requires Onconetix shareholder and regulatory approvals.
Loan of up to $5.0 million to Realbotix, with $2.5 million advanced on September 11, 2026; note matures September 11, 2027
Note is non-interest bearing until the Share Exchange Agreement closes or terminates; 12% annual interest accrues if terminated
At closing, the note is cancelled and the required Net Cash at Closing rises by $500,000 plus the outstanding principal
Realbotix Corp. guarantees the note; closing requires at least $12.5 million in Net Cash
The FDA approved Biofrontera's supplemental New Drug Application for Ameluz with the BF-RhodoLED lamp for superficial basal cell carcinoma in adults. The company says this makes Ameluz the first and only photodynamic therapy approved by the FDA for a skin cancer, and that it expands the addressable market. The filing gives no revenue, sales or financial impact figures.
FDA approval announced September 14, 2026 for Ameluz with BF-RhodoLED lamp for superficial basal cell carcinoma in adults
Phase 3 trial in 187 adults: 66% (95 of 145) of Ameluz PDT subjects achieved the primary endpoint versus 5% (2 of 42) on placebo-PDT
Company plans an official launch of the new indication late in Q4 2026 through Q1 2027, using its existing commercial organization and lamp base
Cardiff Oncology and Nerviano Medical Sciences agreed on September 14, 2026 to settle their pending litigation, with both parties dismissing the case with prejudice and exchanging mutual releases, and no monetary payment made between them. The companies also amended the 2017 license agreement for onvansertib, changing exclusivity, royalty, milestone, governance and assignment terms, which matters to shareholders because it reshapes the economics and conditions of the company's lead asset.
Settlement and Amendment dated September 14, 2026; the Amendment takes full effect when the case is dismissed with prejudice.
No monetary payment was made by either party to resolve the litigation, and neither party admitted liability.
Amendment adds an additional license fee on annual net sales of products practicing a valid Company patent claim, in lieu of the existing royalty.
If Cardiff assigns the license, including by merger or change of control, before Phase III data readout, it would owe Nerviano a percentage of transaction proceeds based on Phase III dosing timing.
HealthStream entered into a Second Amendment to its revolving credit agreement with Truist Bank as administrative agent, keeping the $50 million facility on terms consistent with the prior agreement. The amendment extends the facility's maturity to September 10, 2031 and sets initial interest margins and a commitment fee, giving the company continued access to revolving credit under unsecured terms.
Revolving loans up to $50 million, with $5 million sublimits for swingline loans and standby letters of credit
Credit facility matures September 10, 2031; the company can seek to increase availability by up to $25 million, subject to lender commitments
Initial applicable margins of 0.50% for base rate loans and 1.50% for SOFR loans; initial commitment fee of 20 basis points per annum
Financial covenants require a net funded debt leverage ratio of not more than 3.00 to 1.00 and an interest coverage ratio of not less than 3.00 to 1.00
The Baldwin Insurance Group agreed to be acquired by an entity formed by Sequence Holdings and DFO Management, the Dell family investment office, in an all-cash deal. Shareholders would receive $32.50 per share, and the transaction implies a total enterprise value of about $7.7 billion, including about $3.1 billion of net debt. The deal requires shareholder and regulatory approvals and is expected to close in Q1 2027, after which Baldwin shares would stop trading on Nasdaq.
Shareholders to receive $32.50 per share in cash, a premium of about 88% to the unaffected closing price on June 17, 2026
Equity purchase price of about $4.6 billion and total enterprise value of about $7.7 billion, implying about 20x trailing-twelve-month Adjusted EBITDA of about $396 million
Expected close in Q1 2027, subject to shareholder approval, regulatory approvals and other customary conditions
Shares would be delisted from Nasdaq and deregistered under the Exchange Act after the effective time
XBP Global Holdings agreed on September 11, 2026 to sell 2,275,245 common shares in a private placement to accredited investors at a weighted price of about $2.66 per share, for gross proceeds of about $6.05 million. Insiders, including the CEO, CFO, and affiliates of the Executive Chairman and a board member, were among the buyers, which the company disclosed.
Shares sold at a weighted price of about $2.66; gross proceeds of about $6.05 million, with closing expected on or before September 15, 2026
CEO Andrej Jonovic bought 31,500 shares and CFO Dejan Avramovic bought 8,833 shares; the remaining shares were sold at $2.55
Company must file a resale registration statement by September 22, 2026; officers, directors and certain stockholders agreed to a lock-up of up to 60 days after closing
Immersion reported first-quarter fiscal 2027 results for the three months ended July 31, 2026, with total revenues of $294.4 million, up from $292.0 million a year earlier, and GAAP net income attributable to Immersion stockholders of $4.9 million, or $0.17 per diluted share, versus a loss of $0.9 million a year earlier. Non-GAAP net income attributable to Immersion stockholders was $16.6 million, or $0.50 per diluted share, slightly below $0.52 a year earlier. The Board also declared a quarterly dividend of $0.075 per share payable October 30, 2026.
Total revenues of $294.4 million vs. $292.0 million in the same quarter last year; the consolidated figures include Barnes & Noble Education
GAAP net income attributable to Immersion stockholders of $4.9 million, or $0.17 per diluted share, vs. a loss of $(0.9) million, or $(0.03) per share, a year earlier
Non-GAAP net income attributable to Immersion stockholders of $16.6 million, or $0.50 per diluted share, vs. $16.9 million, or $0.52, a year earlier
Quarterly cash dividend of $0.075 per share payable October 30, 2026, to holders of record on October 16, 2026
SmartKem, Inc. received notice from Nasdaq on September 10, 2026 that it has regained compliance with the $1.00 minimum bid price requirement, and the Staff has closed the matter. The company had received a deficiency notice on March 5, 2026, so the stock has avoided a listing-related threat that had been pending since then.
Nasdaq Staff notified SmartKem on September 10, 2026 that it regained compliance with Listing Rule 5550(a)(2).
The closing bid price was at or above $1.00 per share for 13 consecutive business days, from August 21 through September 9, 2026.
The company first received the minimum bid price notice from Nasdaq on March 5, 2026.
Future Vision II Acquisition Corp. issued a $65,000 non-interest-bearing promissory note to its sponsor, Hwei Super Speed Co., Ltd., to fund a one-month extension of its deadline to complete a business combination, moving the date from September 13, 2026 to October 13, 2026. The note is forgiven if no business combination is completed, and the company states there is no assurance it will close a deal by October 13, 2026.
Promissory note of $65,000 issued September 10, 2026 to sponsor Hwei Super Speed Co., Ltd.
Business combination deadline extended from September 13, 2026 to October 13, 2026
August 2026 extension redemptions paid at $11.03 per share
Company continues to pursue its merger with MicroTouch Technology Inc. under a January 16, 2026 agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.